As Anti-angiogenesis Evolves Into Likely HCS Market, Kentucky Team Hopes to Build Assay | GenomeWeb

More than a decade after Judah Folkman suggested that anti-angiogenesis could be a new approach to treating cancer, drug makers have been trying to develop therapeutics that inhibit the supply of blood to solid tumors.

More recently, a small number of cell-based assay and high-content screening developers have been trying to apply their technologies and methodologies to the angiogenesis space in the hopes that pharmas will use their tools in drug discovery [see sidebar].

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.